Lin, Z.-Y.; Yeh, M.-L.; Liang, P.-C.; Hsu, P.-Y.; Huang, C.-F.; Huang, J.-F.; Dai, C.-Y.; Yu, M.-L.; Chuang, W.-L.
Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy. Cancers 2023, 15, 5097.
https://doi.org/10.3390/cancers15205097
AMA Style
Lin Z-Y, Yeh M-L, Liang P-C, Hsu P-Y, Huang C-F, Huang J-F, Dai C-Y, Yu M-L, Chuang W-L.
Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy. Cancers. 2023; 15(20):5097.
https://doi.org/10.3390/cancers15205097
Chicago/Turabian Style
Lin, Zu-Yau, Ming-Lun Yeh, Po-Cheng Liang, Po-Yao Hsu, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, and Wan-Long Chuang.
2023. "Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy" Cancers 15, no. 20: 5097.
https://doi.org/10.3390/cancers15205097
APA Style
Lin, Z. -Y., Yeh, M. -L., Liang, P. -C., Hsu, P. -Y., Huang, C. -F., Huang, J. -F., Dai, C. -Y., Yu, M. -L., & Chuang, W. -L.
(2023). Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy. Cancers, 15(20), 5097.
https://doi.org/10.3390/cancers15205097
